1. Aboudounya MM, Heads RJ (2021). COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression,Facilitating Entry and Causing Hyperinflammation. DOI: 10.1155/2021/8874339

2. Alhabibi AM, Hassan AS еt al.(2023). Impact of Toll-Like Receptor 2 and 9 Gene Polymorphisms on COVID-19: Susceptibility, Severity, and Thrombosis. J Inflamm Res. 2023 Feb 17;16:665-675. DOI: 10.2147/JIR.S394927.

3. Ali HN, Niranji SS, Al-Jaf SM(2022).Association of Toll-like receptor-4 polymorphism with SARS CoV-2 infection in Kurdish Population. DOI: 10.1016/j.humgen.2022.201115

4. Atyeo C, DeRiso E et al.(2021). COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and nonpregnant women. Sci. Transl. Med. 13, eabi8631

5. Chen N et al.(2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513. DOI: 10.1128/CMR.00032– 09.

6. Charuta A, Smuniewska M, et al.(2023).Effect of COVID-19 on Pregnancy and Neonate's Vital Parameters: A Systematic Review. J Pregnancy. 2023 May 13;2023:3015072. DOI: 10.1155/2023/3015072.

7. Chi J, Gong W, Gao Q (2021) Clinical characteristics and outcomes of pregnant women with COVID-19 and the risk of vertical transmission: a systematic review. Arch Gynecol Obstet 303(2):337–345

8. Collier A-RY et al. (2021). Immunogenicity  of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. DOI: 10.1001/ jama.2021.7563.

9. Drannyk HM, Prylutskyi OS, Bazhora YuI, Kresiun VI, Hodziieva IM, Chopiak VV. [Clinical immunology and allergology]. Edited by H.M. Drannуk. Kyiv: Health: 2006. 888 р. [in Ukrainian].

10.Dong L et al.(2020) Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA 323:1846–1848

11.Filimonov VI, Marakushin DI. [General physiology]. Kyiv: Medicine: 2022. 776 р. [in Ukrainian].

12.Gong, J. et al.(2020). Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. Preprint at medRxiv DOI : 10.1101/2020.02.25.20025643.

13.Hikmet F et al (2020) The protein expression profle of ACE2 in human tissues. Mol Syst Biol 16:e9610

14.Hofmann M et al.(2020) The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular Archives of protease TMPRSS2 for entry into target cells. BioRxiv. DOI: 10.1101/2020.01.31.929042

15.Hosier H, Farhadian SF, Morotti RA et al.(2020). SARS–CoV-2 infection of the placenta. J Clin Investig. 2020 DOI: 10.1172/JCI139569. 16.Huang, C. et al.(2020).Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

17.Imai, Y. et al. (2008).Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235–249.

18.Jafarzadeh A, et al.(2020).Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102. DOI: 10.1016/j. lfs.2020.118102.

19.Karki R, Kanneganti T (2022 ). Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. Nov 22;20(1):542. DOI: 10.1186/ s12967-022-03767-z.

20.Komine-Aizawa S, Takada K, Hayakawa S (2020) Placental barrier against COVID-19. Placenta 99:45–49

21.Kramarev SА, Yevtushenko VV. [Experience with application of nasal interferon in the treatment and prevention of acute respiratory infection]. ACTUAL INFECTOLOGY. 2019. 7(4):217-223. [in Ukrainian]. DOI:10.22141/2312-413x.7.4.2019.178883

22.Kurchenko AI. [Course of lectures on clinical immunology and allergology with the section of medical genetics, NMU named after O.O. Bogomoletsa, Kyiv, 2023 ]. [in Ukrainian].

23. Langel SN, Otero CE, Martinez DR(2020). Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. PLOS Pathog. 16, e1008303

24.Mehta P et al.(2020).COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034.

25.Mirbeyk M, Saghazadeh A, Rezaei N (2021) A systematic review of pregnant women with COVID-19 and their neonates. Arch Gynecol Obstet 304(1):5–38.

26.Merad M, Martin JC. (2020). Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020 Jun; 20(6):355-362. Epub 2020 May 6. DOI: 10.1038/s41577-020-0331-4.

27.Morton SU, Brodsky D. Fetal physiology and the transition to extrauterine life. Clin Perinatol. (2016) 43:395–407. DOI:10.1016/j. clp.2016.04.001

28.Ovies C, Semmes EC, Coyne CB. Pregnancy influences immune responses to SARS-CoV-2. Sci Transl Med. 27;13(617): eabm2070. DOI: 10.1126/scitranslmed.abm2070.

29.Pettirosso E et al (2020). COVID-19 and pregnancy: a review ofclinical characteristics, obstetric outcomes and vertical transmission. Aust N Z J Obstet Gynaecol 60:640–659

30.Qiu L, et al. (2020). SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection. Clin Infect Dis. 2020;71:813–817. DOI: 10.1093/cid/ciaa375.

31.Rich R, Fleisher T(2023). Clinical immunology: principles and practice. Book. sixth ed., 2023. DOI: 10.1016/C2019-0-00545-6

32.Richardson, S. et al.(2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA DOI: 10.1001/jama.2020.6775.

33.Ruan, Q, Yang, K, Wang, W et al.(2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. DOI: 10.1007/s00134-020-05991-x.

34. Sanche, S, Cassidy, T, Chu, P. et al. (2022). A simple model of COVID-19 explains disease severity and the effect of treatments. Sci Rep 12, 14210. DOI: 10.1038/s41598-022-18244-2

35.Shirobokov VP, Klimnyuk SI(2021). [Medical microbiology, virology and immunology]. Vinnytsia: New book. 2021. 920 p. [in Ukrainian].

36.Swanson JR, Sinkin RA. Transition from fetus to newborn. Pediatr Clin North Am. (2016) 62:329–43. DOI: 10.1016/j.pcl.2014.11.002.

37.Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. American Society for Microbiology (ASM); 2010 [cited 2019 Sep 15]. 23. 74-98. Available on: http://www.ncbi.nlm. nih.gov/ pubmed/20065326.

38.Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical clinical symptoms, virology, and immunology. DOI: 10.1128/CMR.00032-09

39.Valdespino-Vázquez MY, et al. Fetal and placental infection with SARS-CoV-2 in early pregnancy. J Med Virol. 2021;93:4480–4487. DOI: 10.1002/jmv.26965.

40.Villar J, Arif S et al. (2021) Maternal and neonatal morbidity and mortality among pregnant women with andwithout COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. DOI: 10.1001/ jamapediatrics.2021.1050

41.Vorobіova OV, Melnyk OO. (2023). MIS (Kawasaki-like multisystem inflammatory syndrome) as a manifestation of SARS-CoV-2 in newborns: a review of the literature. Modern Pediatrics. Ukraine. 8(136): 106-115. DOI: 10.15574/SP.2023.136.106.

42.Wang, J, Dong, W. COVID-19: the possibility, ways, mechanisms, and interruptions of mother-to-child transmission. Arch Gynecol Obstet 307, 1687–1696 (2023). DOI: 10.1007/ s00404-022-06639-5

43.Wu, C. et al. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. DOI: 10.1001/jamainternmed.2020.0994.

44.Xu, Z. et al. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420– 422.

45.Xi C, Guili W (2020) a review of pregnancy outcomes of novel coronavirus infection during pregnancy. Acta Laser Biol Sin 32.29:302–308